Samir Kaul is a Founding Partner and Managing Director at Khosla Ventures, focused on health, sustainability, food, and advanced tech. He led investments in companies with notable exits, including Vicarious Surgical, View, Guardant Health, Nutanix, Oscar, Quantumscape, and Raxium. Other investments include Impossible Foods, Mojo Vision, Statespace, Varda Space, and Ultima Genomics.
Previously, Samir spent five years at Flagship Ventures, where he started and invested in early stage biotech companies. While there, he helped co-found Helicos BioSciences with Stanford’s Stan Lapidus and Steve Quake, which was a leader in developing single-molecule sequencing instruments to revolutionize personalized medicine. He was also founding CEO of Codon Devices. His investments include Epitome (Millipore), LS9 (Renewable Energy Group) and Morphotek (Eisai).
Previously, Samir led the Arabidopsis Genome Initiative at Craig Venter’s Institute for Genomic Research. Under his direction, the cost-efficient project was completed early and led to publication in the December 2000 issue of Nature. He holds a degree from the University of Michigan and an MBA from Harvard Business School.
